References
- Camela E, Potestio L, Fabbrocini G, et al. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther England. 2022;22(12):1431–1433. DOI:10.1080/14712598.2022.2113872
- Vičić M, Kaštelan M, Brajac I, et al. Current Concepts of Psoriasis Immunopathogenesis. Int J Mol Sci. 2021;22(21):22. DOI:10.3390/ijms222111574
- Singh R, Koppu S, Perche PO, et al. The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. Int J Mol Sci. 2021;22(23):22. DOI:10.3390/ijms222312793
- Reid C, Griffiths CEM. Psoriasis and Treatment: past, Present and Future Aspects. Acta Derm Venereol. 2020;100(3):70–80.
- Camela E, Potestio L, Ruggiero A., et al. Towards Personalized Medicine in Psoriasis: Current Progress. Psoriasis (Auckl). 2022Sep 1 ;12:231–250. PMID: 36071793; PMCID: PMC9444142. DOI:10.2147/PTT.S328460
- Bachelez H, Choon S-E, Marrakchi S, et al. Trial of Spesolimab for Generalized Pustular Psoriasis. N Engl J Med. 2021;385:2431–2440.
- Mrowietz U, Burden AD, Pinter A, et al. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb). 2021;11:571–585.
- International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02762994?cond=BCD-085&draw=2&rank=6 (last access Jan 22 2023).
- An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (BCD-085-7). Available from:https://clinicaltrials.gov/ct2/show/results/NCT03390101?cond=BCD-085&draw=2&rank=7 (last access Jan 15 2023).
- Puig L, Bakulev AL, Kokhan MM, et al. Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatol Ther (Heidelb). 2021;11:1319–1332.
- Reich K, Rich P, Maari C, et al. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol. 2019;181:88–95.
- Papp KA, Warren RB, Green L, et al. Efficacy and safety of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe psoriasis: 52-week results from OASIS-2, a multicenter, randomized, double-blind study. J Clin Aesthet Dermatol. 2021;14(5 Suppl. 1):S8–30.
- Blauvelt A, Kimball AB, Augustin M, et al. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). Br J Dermatol. 2022;187:866–877.
- A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3). Availble from: https://clinicaltrials.gov/ct2/show/NCT03556202 (last access Jan 29 2023).
- Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018;379:1313–1321.
- Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29–39. DOI:10.1016/j.jaad.2022.07.002
- Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51. DOI:10.1016/j.jaad.2022.08.061
- Singh RSP, Pradhan V, Roberts ES, et al. Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: a Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study. Clin Transl Sci. 2021;14:671–682.
- Tehlirian C, Singh RSP, Pradhan V, et al. Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2022;87(2):333–342. DOI:10.1016/j.jaad.2022.03.059
- Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949–961.
- Valenzuela F, Paul C, Mallbris L, et al. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. J Eur Acad Dermatol Venereol. 2016;30:1753–1759.
- Papp K, Pariser D, Catlin M, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015;173:767–776.
- Efficacy of Roflumilast in the Treatment of Psoriasis (PSORRO). Available from: https://clinicaltrials.gov/ct2/show/NCT04549870?cond=roflumilast&draw=17&rank=35 (last access last access 28 2023).
- Roflumilast Versus Methotrexate in Psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT05684744?cond=roflumilast&draw=4&rank=24 (last access Jan 19 2023).
- Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet (London, England). 2014;384(9959):2036–2045. DOI:10.1016/S0140-6736(14)60803-5
- Pariser DM, Bagel J, Lebwohl M, et al. Serlopitant for psoriatic pruritus: a phase 2 randomized, double-blind, placebo-controlled clinical trial. J Am Acad Dermatol. 2020;82(6):1314–1320. DOI:10.1016/j.jaad.2020.01.056
- Yosipovitch G, Ständer S, Kerby MB, et al. Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol. 2018;78(5):882–891.e10. DOI:10.1016/j.jaad.2018.02.030
- Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch). Available from: https://clinicaltrials.gov/ct2/show/results/NCT03540160 (last access Jan 2, 2023).
- Safety and Efficacy Study of CF101 to Treat Psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT00428974?cond=cf-101&draw=2&rank=10 (last access Jan 11, 2023).
- Trial of CF101 to Treat Patients With Psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT01265667?cond=cf-101&draw=2&rank=4 (last access Jan 12, 2023).
- CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03168256?cond=cf-101&draw=2&rank=2&view=record (last access Feb 9 2023).
- HA B. Spesolimab: first Approval. Drugs. 2022;82:1681–1686.
- An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options. Available from: https://clinicaltrials.gov/ct2/show/NCT05200247?cond=spesolimab&draw=2&rank=5 (last access Jan 9 2023).
- Erdes S, Nasonov E, Kunder E, et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol. 2020;38:27–34.
- Wang P, Zhang S, Hu B, et al. Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2021;40:3053–3065.
- Bryushkova EA, Skatova VD, Mutovina ZY, et al. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: an observational study. PLoS ONE. 2022;17:e0273340.
- Salimi S, Yamauchi PS, Thakur R, et al. Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: a narrative review. Dermatol Ther. 2020;33:e13800.
- A Safety Study of Mirikizumab (LY3074828). Available from: https://clinicaltrials.gov/ct2/show/study/NCT01947933?cond=mirikizumab&draw=3&rank=19 (last access Jan 18 2023).
- A Study of Mirikizumab in Participants With Plaque Psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT03718884?cond=mirikizumab&draw=4&rank=3 (last access Jan 12 2023).
- Roskoski RJ. Deucravacitinb is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacol Res. 2023;106642:106642.
- Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81:815–822.
- Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):11. DOI:10.1126/scitranslmed.aaw1736
- A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT04772079?cond=deucravacitinib&draw=3&rank=12 (last access Jan 29, 2023).
- Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT05478499?cond=deucravacitinib&draw=2&rank=6 (last access Jan 17, 2023).
- An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT05124080?cond=deucravacitinib&draw=3&rank=15 (last access Feb 5, 2023).
- A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan. Available from: https://clinicaltrials.gov/ct2/show/NCT05633264?cond=deucravacitinib&draw=2&rank=1 (last access Jan 12, 2023).
- Martin G. Novel Therapies in Plaque Psoriasis: a Review of Tyrosine Kinase 2 Inhibitors. Dermatol Ther (Heidelb). 2023;13:417–435.
- Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019;78:1305–1319.
- Naseem S, Hassan M, Akhtar SN, et al. Effectiveness of Roflumilast in Treating Chronic Obstructive Pulmonary Disease: a Systematic Review and Meta-Analysis. Cureus. 2022;14:e22843.
- Topical roflumilast (Zoryve) for plaque psoriasis. Med Lett Drugs Ther. 2023;65:10–12. DOI:10.58347/tml.2023.1668b
- Bondarev AD, Attwood MM, Jonsson J, et al. Recent developments of phosphodiesterase inhibitors: clinical trials, emerging indications and novel molecules. Front Pharmacol. 2022;13:1057083.
- Ryan C, Menter A Ponesimod–a future oral therapy for psoriasis? Lancet. 2014Dec 6;384(9959):2006–2008. DOI:10.1016/S0140-6736(14)61039-4. Epub 2014 Aug 10. PMID: 25127207.
- Ständer S, Spellman MC, Kwon P, et al. The NK1 receptor antagonist serlopitant for treatment of chronic pruritus. Expert Opin Investig Drugs. 2019;28(8):659–666. DOI:10.1080/13543784.2019.1638910
- Fishman P. Drugs Targeting the A3 Adenosine Receptor: human Clinical Study Data. Molecules. 2022 Jun 8;27(12):3680. DOI:10.3390/molecules27123680. PMID: 35744805; PMCID: PMC9229414.
- Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis. Available from: https://www.businesswire.com/news/home/20220629005222/en/%C2%A0Can-Fite-Announces-Positive-Top-Line-Results-from-Piclidenoson-Phase-III-COMFORT%E2%84%A2-Study-in-Moderate-to-Severe-Psoriasis (last access Jan 12, 2023).
- A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment. Available from: https://clinicaltrials.gov/ct2/show/NCT05376839 (last access Jan 7, 2023).
- A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis. Available from: https://clinicaltrials.gov/ct2/show/NCT05044234 (las las 12, 2023).
- Clebak KT, Helm LA, Foulke G, et al. Autoimmune Skin Conditions: psoriasis. FP Essent. 2023;526:7–12.
- Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023;22:43–58.
- Megna M, Potestio L, Fabbrocini G, et al. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;22(12):1503–1520. DOI:10.1080/14712598.2022.2089020
- Camela E, Potestio L, Fabbrocini G, et al. Paradoxical reactions to biologicals for psoriasis. Expert Opin Biol Ther England. 2022;22(12):1435–1437. DOI:10.1080/14712598.2022.2153593
- Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther United States. 2022;35(12):e15941. DOI:10.1111/dth.15941